Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (VRDN) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.
The live webcast will be available via the Investors “Events and Presentations” section of viridiantherapeutics.com, with a replay provided after the event. The company develops therapies for autoimmune and rare diseases, including Lumvoa, an FDA‑approved IGF‑1R antagonist for thyroid eye disease, and elegrobart, a late‑stage investigational subcutaneous TED therapy.
Viridian Therapeutics (Nasdaq: VRDN) reported Q2 2026 results and major pipeline and commercial progress. The FDA approved Lumvoa for thyroid eye disease (TED) on June 26, 2026, ahead of its target date, and Viridian immediately launched the drug in the U.S.
By July 31, the company’s field team had engaged 95% of 2,000 core prescribing physicians, with payer coverage efforts on track and first Lumvoa doses administered in July. Viridian is preparing a Q1 2027 BLA submission for elegrobart after positive phase 3 REVEAL-1 and REVEAL-2 results in active and chronic TED. IND submission for its TSHR antibody is planned for Q4 2026, and phase 1 data for FcRn inhibitor VRDN-008 remain on track for 2H 2026.
Cash, cash equivalents, and marketable securities were $981.5 million at June 30, 2026, supported by $394 million of May 2026 financing. Q2 2026 revenue was $0.3 million and net loss was $127.1 million, with lower R&D and higher SG&A as Viridian scales commercial operations.
Viridian Therapeutics (Nasdaq: VRDN) received U.S. FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease (TED) regardless of disease activity or duration and plans an immediate U.S. launch.
Approval followed Priority Review and two pivotal phase 3 THRIVE trials covering both active and chronic TED.
Viridian Therapeutics (Nasdaq: VRDN) will participate in two June 2026 investor conferences. Management will host fireside chats at the Jefferies Global Healthcare Conference on June 3, 2026, at 5:30pm ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 4:00pm ET in Miami. Live webcasts and replays will be available in the Investors section of Viridian’s website.
Viridian Therapeutics (Nasdaq: VRDN) priced upsized concurrent offerings: $225.0 million aggregate principal of 1.75% convertible senior notes due 2032 and 7,352,942 shares of common stock at $17.00 per share, for aggregate gross proceeds of $350.0 million.
Viridian estimates aggregate net proceeds of approximately $334.7 million. Offerings are expected to close on May 11, 2026. Net proceeds will repay Hercules loan, fund TED market expansion studies, advance early pipeline R&D, and for working capital.
Viridian Therapeutics (Nasdaq: VRDN) announced proposed concurrent public offerings of $150.0 million aggregate principal amount of convertible senior notes due 2032 and $100.0 million of equity (common stock and Series B non-voting convertible preferred stock) on May 5, 2026. Each Series B share converts into 66.67 common shares subject to ownership limits. The offerings include 30-day 15% overallotment options for underwriters. Proceeds are intended to repay outstanding indebtedness to Hercules Capital, fund TED market expansion studies, advance earlier pipeline R&D, and for working capital. Pricing and final terms remain subject to market conditions and SEC prospectus filings.
Viridian Therapeutics (Nasdaq: VRDN) reported Q1 2026 progress including a PDUFA target date of June 30, 2026 for veligrotug and an EMA MAA accepted for review after a January 2026 submission. Elegrobart posted positive pivotal REVEAL-1 and REVEAL-2 topline data; a BLA is anticipated in Q1 2027. Cash and marketable securities were $762.2M as of March 31, 2026. VRDN-006 and VRDN-008 remain on-track for 2026 development updates and 2H 2026 phase 1 data, respectively.
Viridian Therapeutics (Nasdaq: VRDN) announced positive topline results from the REVEAL-2 phase 3 trial of subcutaneous elegrobart in chronic thyroid eye disease (TED). REVEAL-2 (n=204) met FDA and EMA primary endpoints: proptosis responder rates were 50% (Q4W) and 54% (Q8W) versus 15% placebo (p < 0.0001). Mean proptosis change: -1.9 mm (Q4W) and -2.1 mm (Q8W) vs -0.5 mm placebo. Q4W diplopia responder rate was 61% vs 38% placebo (p=0.0118). Safety was generally consistent with prior data; 91% completed treatment. BLA submission is on track for Q1 2027.
Viridian Therapeutics (Nasdaq: VRDN) reported positive topline REVEAL-1 Phase 3 results for subcutaneous elegrobart in active thyroid eye disease (TED). Q4W and Q8W arms showed proptosis responder rates of 54% and 63% versus 18% placebo at week 24. Diplopia resolved in 51% (Q4W) versus 16% placebo. Safety was generally well tolerated; low tinnitus reports. Viridian ended Q4 2025 with $875 million cash. REVEAL-2 topline is on track for Q2 2026 and a BLA is anticipated in Q1 2027.
Viridian Therapeutics (Nasdaq: VRDN) reported Q4 and full-year 2025 results and program updates. Key items: PDUFA target date June 30, 2026 for veligrotug in TED, MAA submitted to EMA in January 2026, REVEAL‑1 and REVEAL‑2 topline readouts on track in Q1 and Q2 2026, VRDN‑008 IND cleared and phase 1 started, and $874.7M cash as of December 31, 2025. The company expects existing cash, anticipated milestones, and potential commercial revenues to fund plans through profitability if lead programs are approved.